Page 2,675«..1020..2,6742,6752,6762,677..2,6802,690..»

Global Markets for Stem Cells

Posted: September 7, 2012 at 6:11 am

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0958103/Global-Markets-for-Stem-Cells.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

INTRODUCTION

The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.

REASONS FOR DOING THE STUDY

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced a number of significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

SCOPE OF REPORT

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories quantified and forecast include cancer, CNS diseases, infections and cardiovascular. Major country markets in three regionsAmericas, Europe and Asiaare analyzed and forecast, with a summary for the rest of the world.

The rest is here:
Global Markets for Stem Cells

Posted in Stem Cells | Comments Off on Global Markets for Stem Cells

CIRM’s latest round of funding

Posted: September 7, 2012 at 6:11 am

>>UC Irvine photos

The California Institute for Regenerative Medicine awarded $63 million in CIRM Disease Team Therapy Development Awards to four research teams. UCLA's Stanley Nelson and collaborators also are recipients, for research on Duchenne muscular dystrophy.

CIRM also granted Basic Biology IV awards to a number of UC researchers:

UC Berkeley: Robert Tjian UC Davis: Deborah Lieu UCLA: Kathrin Plath, Owen Witte UC San Diego: George Sen, Gene Yeo, Maike Sander, Ananda Goldrath, Miles Wilkinson, David Traver UC San Francisco: Jeremy Reiter, Barbara Panning, Miguel Ramalho-Santos

>>CIRM press release

IRVINE Efforts to begin human clinical trials using stem cells to treat Alzheimer's disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Wednesday (Sept. 5).

UC Irvine scientists will be part of two research teams garnering CIRM Disease Team Therapy Development Awards, which are designed to accelerate collaborative translational research leading to human clinical trials. In one, Dr. Henry Klassen, an associate professor of ophthalmology in UC Irvine's Sue & Bill Gross Stem Cell Research Center, and his collaborators at UC Santa Barbara and Cedars-Sinai Medical Center, received $17.3 million to cultivate therapeutically potent retinal progenitor stem cells to treat the blinding effects of retinitis pigmentosa.

In the other, StemCells, Inc. in Newark, Calif., received $20 million and will collaborate with Frank LaFerla and Mathew Blurton-Jones neurobiologists with the stem cell research center and the Institute for Memory Impairments and Neurological Disorders (UCI MIND) to advance research using the company's proprietary purified human neural stem cells to improve memory in people with Alzheimer's disease.

"CIRM's support for UC Irvine's efforts to advance stem cell-based treatments for a variety of diseases is extremely gratifying," said Peter Donovan, director of the Sue & Bill Gross Stem Cell Research Center. "Henry's work on retinitis pigmentosa and Frank and Mathew's on Alzheimer's disease hold great promise, and we are delighted that they have the support to see their work move toward the clinic."

Klassen's objective is to introduce stem cells that rescue and reactivate damaged and dying photoreceptor rods and cones, thus reversing the course of RP even at relatively advanced stages. The current CIRM funding will allow Klassen and his collaborators to grow these cells under conditions ensuring that pharmaceutical standards are met. The resulting cells will be tested in animals for safety and to make certain that they are therapeutically potent. Then the team will seek FDA approval for the use of these cells in early clinical trials, in which a small number of patients with severe RP will be injected with cells in their worse-seeing eye and followed clinically for a specified period of time to determine the safety and effectiveness of the treatment.

Original post:
CIRM's latest round of funding

Posted in Stem Cells | Comments Off on CIRM’s latest round of funding

StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer’s Disease …

Posted: September 7, 2012 at 6:11 am

NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of StemCells' proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in Alzheimer's disease over a maximum four-year period, with the goal of filing an investigational new drug (IND) application for a clinical trial in that time. In July, CIRM approved a separate award to the Company under RFA 10-05 for up to $20 million to fund preclinical development of HuCNS-SC cells in cervical spinal cord injury.

"With the recent spate of late-stage clinical failures in Alzheimer's disease, it is clear that the field could benefit from alternative approaches to lessen the huge burden on families, caregivers and our healthcare system," commented Martin McGlynn, President and CEO of StemCells, Inc. "Our recently reported preclinical data, which showed that our neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease, shows our approach has promise. We greatly appreciate the support from CIRM, which should help us accelerate our efforts to test our HuCNS-SC cells in Alzheimer's disease."

StemCells will evaluate its HuCNS-SC cells as a potential treatment for Alzheimer's disease in collaboration with Frank LaFerla, Ph.D., a world-renowned researcher in the field. Dr. LaFerla is Director of the University of California, Irvine (UCI) Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Chancellor's Professor, Neurobiology and Behavior in the School of Biological Sciences at UCI.

Mr. McGlynn added, "CIRM's approval of two awards to StemCells illustrates the tremendous promise of our neural stem cell technology and the high degree of confidence in the world class team of scientists and clinicians who will be working to translate this technology into potential treatments and cures for these devastating diseases."

About CIRM

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding; the potential of the Company's HuCNS-SC cells to treat a broad range of central nervous system disorders such as Alzheimer's disease and spinal cord injury; the prospect of initiating a clinical trial in Alzheimer's disease or cervical spinal cord injury; the timing and prospects for funding by the California Institute for Regenerative Medicine; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the results of the Company's preclinical studies will be replicated in humans; uncertainties about the prospect and timing of entering into the agreements necessary to receive funding from CIRM and whether the Company will satisfy, and continue to satisfy, all preconditions for such funding; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and in its subsequent reports on Forms 10-Q and 8-K.

Excerpt from:
StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease ...

Posted in Regenerative Medicine | Comments Off on StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer’s Disease …

Diabetes study hit by lack of funds

Posted: September 7, 2012 at 6:10 am

Lack of funds for a diabetes study is putting at risk work that could place Dunedin at the forefront of stem cell research, University of Otago haematologist and cell biologist Dr Jim Faed says.

In the wake of the global financial crisis, traditional funding sources had "dried up", he said.

Preliminary laboratory work for the stem cell research on diabetes type 1 sufferers at the Spinal Cord Society Research Laboratory has been put on hold.

However, it was hoped public support would get the study back on track and see it start next year, as planned.

Only a few thousand dollars of the $1.8 million needed had been raised, but project leaders were determined to stay positive, he said.

The trial had the potential to find a cure for, or improve the treatment of, diabetes type 1 and other autoimmune diseases.

"This is much bigger than I think many people have realised. We are standing on the brink of huge change in how a number of diseases are going to be treated. I think, in the next few years, we're going to see these diseases tackled effectively."

The trial would build on Chicago research that demonstrated improvement in diabetes type 1 sufferers with use of stem cells from umbilical cords.

Umbilical cord stem cells were shown to increase insulin production in even the most severe diabetics.

The Dunedin study would replicate the study, using stem cell tissue from bone marrow.

Continue reading here:
Diabetes study hit by lack of funds

Posted in Diabetes | Comments Off on Diabetes study hit by lack of funds

StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease …

Posted: September 6, 2012 at 3:14 pm

NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of StemCells' proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in Alzheimer's disease over a maximum four-year period, with the goal of filing an investigational new drug (IND) application for a clinical trial in that time. In July, CIRM approved a separate award to the Company under RFA 10-05 for up to $20 million to fund preclinical development of HuCNS-SC cells in cervical spinal cord injury.

"With the recent spate of late-stage clinical failures in Alzheimer's disease, it is clear that the field could benefit from alternative approaches to lessen the huge burden on families, caregivers and our healthcare system," commented Martin McGlynn, President and CEO of StemCells, Inc. "Our recently reported preclinical data, which showed that our neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease, shows our approach has promise. We greatly appreciate the support from CIRM, which should help us accelerate our efforts to test our HuCNS-SC cells in Alzheimer's disease."

StemCells will evaluate its HuCNS-SC cells as a potential treatment for Alzheimer's disease in collaboration with Frank LaFerla, Ph.D., a world-renowned researcher in the field. Dr. LaFerla is Director of the University of California, Irvine (UCI) Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Chancellor's Professor, Neurobiology and Behavior in the School of Biological Sciences at UCI.

Mr. McGlynn added, "CIRM's approval of two awards to StemCells illustrates the tremendous promise of our neural stem cell technology and the high degree of confidence in the world class team of scientists and clinicians who will be working to translate this technology into potential treatments and cures for these devastating diseases."

About CIRM

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding; the potential of the Company's HuCNS-SC cells to treat a broad range of central nervous system disorders such as Alzheimer's disease and spinal cord injury; the prospect of initiating a clinical trial in Alzheimer's disease or cervical spinal cord injury; the timing and prospects for funding by the California Institute for Regenerative Medicine; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the results of the Company's preclinical studies will be replicated in humans; uncertainties about the prospect and timing of entering into the agreements necessary to receive funding from CIRM and whether the Company will satisfy, and continue to satisfy, all preconditions for such funding; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and in its subsequent reports on Forms 10-Q and 8-K.

Original post:
StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease ...

Posted in Regenerative Medicine | Comments Off on StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease …

Stem Cell Research and Your Dog

Posted: September 6, 2012 at 4:17 am

By Kim Ribbink, Studio One Networks

Stem cell research often conjures images of political firestorms and futuristic science, yet it's a field that's already offering hope for humans and dogs alike. While the ideal of fixing spinal injuries and curing disease may be a long way off, dogs treated with stem cells are enjoying a new lease on life.

Pepper, a 10-year-old standard poodle, is a case in point. Crippled with arthritis in both his hips, Pepper came to James Gaynor, DVM, M.S., medical director of Animal Anesthesia & Pain Management Center in Colorado Springs, Colo., with his owners, who fully expected to have to put their pet to sleep. Conventional treatments hadn't worked, or had made their dog even sicker. In fact, Pepper's owners were so certain nothing could be done that they bought another puppy. "At our 60 day recheck, the owner was hugging me and crying out of happiness because, in her words, we gave her back her dog," Dr. Gaynor says. "The only problem was she now had Pepper and a puppy."

Healthy Bones It wasn't long ago that dogs like Pepper with arthritis had few options beyond conventional anti-inflammatory treatments -- including a variety of non-steroid anti-inflammatory drugs (NSAIDs) such as Metacam, Previcox, Rimadyl and phenylbutazone; steroid medications such as Prednisone; and disease-modifying osteoarthritis drugs (DMOADs) such as Adequan Canine -- that sometimes don't work. Now stem cells are providing an alternative. One California-based company, Vet-Stem, uses stem cells from dogs' own fat to treat animals in pain.

According to Julie Ryan Johnson, DVM, vice president of sales and marketing, studies have shown that fat is very rich with stem cells, making it an ideal source, and one that is nearly free from controversy, given that most of us don't mind having a bit of fat removed. "The way we do this is a veterinarian will send us a sample of the dog's fat," Dr. Ryan Johnson says. "We isolate the stem cells from that and then send the stem cells back to the veterinarian who injects them back into the dog -- for example, into an arthritic hip or elbow."

Once in the dog, the stem cells communicate with other cells in their environment. While it's not known exactly how they work, they do decrease the dog's pain level. "It's provided the veterinarian with another solution for helping these animals that have pain or difficulty moving," Dr. Ryan Johnson says. "Most importantly, for the dog and the dog owner, it offers quality of life."

The Possibilities Richard Vulliet, Ph.D., DVM, professor and director of the Laboratory of Veterinary Cytotherapeutics at UC Davis, says stem cells haven't cured any diseases yet, but researchers are working hard to change that. "I think that stem cells in general will rewrite the medical textbooks in the next 10 to 20 years," Dr. Vulliet says. "They will have an impact on human, canine, feline and equine health and will allow us to treat diseases that we can only dream about at this time."

Tony Kremer, DVM, an Illinois-based veterinary surgeon, says that as research progresses into the origin of diseases, there is hope that stem cell therapy might one day be used to treat diabetes and muscular dystrophy in dogs. "It is hoped that this research can repair or replace diseased organs, severed spinal cords, or brain cells destroyed by Alzheimer's disease in humans and dogs," he says.

Dr. Vulliet works with adult bone marrow stem cells to investigate potential cures for diseases that cause misery for many dogs. Your dog may soon be able to get breakthrough treatment in the following areas:

Go here to read the rest:
Stem Cell Research and Your Dog

Posted in Stem Cell Videos | Comments Off on Stem Cell Research and Your Dog

OU To Host International Stem Cell Research Conference Oct. 5-7

Posted: September 6, 2012 at 4:17 am

ROCHESTER - The Oakland University William Beaumont Institute for Stem Cell and Regenerative Medicine will welcome both national and international experts in stem cell research and its biotechnological applications when it hosts the Second Midwest Conference on Stem Cell Biology and Therapy set for Oct. 5-7.

Researchers from hospitals, medical organizations, academic institutions and the business community throughout the country will discuss not only the latest advances in this rapidly expanding field of medical science, but the ethical and moral issues that surround it.

Rasul Chaudhry, an OU faculty member, co-director of the ISCRM and a lead organizer of the conference, has studied embryonic and umbilical cord blood stem cells and multipotent progenitors for more than a decade. He said he is looking forward to sharing the work he, colleagues and students have been zealously pursuing.

"This conference provides an excellent opportunity to showcase Oakland University being a world-class institution involved in cutting-edge biomedical research," Chaudhry explained. "This is also a chance to show the high-caliber research efforts that are going on at OU and recognize the efforts of our faculty and students."

Bernard Siegel, executive director of the Genetics Policy Institute (GPI) and founder of the annual World Stem Cell Summit, said, "GPI is proud to partner with ISCRM in this important scientific conference, which will showcase the latest discoveries from top laboratories around the region.

"We are especially proud that the institute was officially launched at the 2010 World Stem Cell Summit in Detroit. We congratulate Dr. Chaudhry for his visionary leadership in organizing this year's regional conference, which will again put Michigan and the entire Midwest on the stem cell map."

This year's event will build on the success of the First Midwest Conference on Stem Cell Biology, which Oakland University, Beaumont Health System and Providence Hospital organized in 2008, as well as the 2010 World Stem Cell Summit organized by the University of Michigan, Wayne State University and Michigan State University. Main highlights of this three-day conference include more than 90 expert speakers and panelists presenting their latest research in one keynote forum, three plenary sessions and 16 focus sessions.

"It is an exciting time for regenerative medicine platforms that aim to integrate stem cell biology, organogenesis and tissue engineering into cell, tissue- and organ-based therapies," said Dr. Gary Hammer, Millie Schembechler Professor of Adrenal Cancer and director of the Endocrine Oncology Program at the University of Michigan Medical School.

"As the University of Michigan's Center for Organogenesis is composed of over 120 faculty engaged in research in these basic and translational disciplines, we are delighted to support and participate broadly in this conference."

Regular registration, which runs through Saturday, Sept. 15, is $350 for the public and $175 for students, residents and post-doctoral students. Registration after Sept. 15 is $400 and $200, respectively. Optional workshops are $100. Sponsorship opportunities are still available.

Go here to read the rest:
OU To Host International Stem Cell Research Conference Oct. 5-7

Posted in Stem Cell Research | Comments Off on OU To Host International Stem Cell Research Conference Oct. 5-7

Pluristem stem cells save 3rd bone marrow disease patient

Posted: September 5, 2012 at 7:10 pm

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today announced that its Placental eXpanded (PLX) cell treatment has saved the life of a third bone marrow disease patient. The treatment at Hadassah Medical Center in Jerusalem, was carried out under Israel's compassionate use procedures.

The patient, a 45-year old man with acute myeloid leukemia (AML), a form of blood cancer, underwent chemotherapy and an unrelated bone marrow transplant, because the chemotherapy also kills normal bone marrow cells. However, he suffered from severe and long standing pancytopenia (lack of white blood cells) with associated complications.

Due to the patient's life threatening condition, 144 days after the bone marrow transplantation, PLX cells were twice injected intramuscularly, one week apart. No local or systemic side effects were observed. In addition, the patient's general clinical condition and wellbeing significantly improved, resulting in his release from Hadassah Medical Center.

Pluristem said that the success of the three treatments with its PLX cells may have significant potential to treat a range of indications of bone marrow diseases.

Professor Reuven Or, Director of the Bone Marrow Transplantation and Cancer Immunology at Hadassah Medical Center handled the treatments. He said, "Following three successful treatments, which were conducted for the first time in the world, in Hadassah Medical Center, we can say that PLX cells from the placenta saved the life of patients suffering from bone marrow failure. We are very encouraged by the results and hope that future clinical trials will show the effectiveness of the PLX cells. I believe that the PLX treatment holds huge hope for patients who suffer from different conditions of bone marrow failure and once approved will be available for every patient who needs it.

Pluristem chairman and CEO Zami Aberman said, "In addition to these three patients, we have data to suggest that our PLX cells may be helpful for rescuing both allogeneic as well as autologous bone marrow transplant failures."

Last month, Pluristem filed documents requesting the US Food and Drug Administration (FDA) to grant orphan drug status for the companys PLX cells for the treatment of aplastic anemia, a critical hematological emergency which is treated by a bone marrow transplantation. There are 30,000 bone marrow transplants a year in the US alone.

Pluristem's share price rose 8.1% after the announcement by mid-afternoon on the TASE today to NIS 18.19, after rising 2.7% on Nasdaq yesterday to $4.19, giving a market cap of $188 million.

Published by Globes [online], Israel business news - http://www.globes-online.com - on September 5, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Read this article:
Pluristem stem cells save 3rd bone marrow disease patient

Posted in Stem Cell Videos | Comments Off on Pluristem stem cells save 3rd bone marrow disease patient

A look at stem cells and their current use

Posted: September 5, 2012 at 7:10 pm

Dear Dr. Donohue Since starting to clip your articles, I haven't found any that deal with using adult stem cells for breakthrough treatments, such as repairing heart damage. Could they help if one needs an aortic valve replacement? A.R.

Answer Stem cells are primitive cells that have the potential of spawning mature cells that carry out specific bodily functions, like skin cells, liver cells, lung cells, heart muscle cells, and on and on. Embryonic stem cells have the greatest potential for differentiating into any of the many varieties of cells that make up all body organs, structures and tissues.

Hematopoietic stem cells are recovered from the bone marrow and, to a lesser extent, the circulating blood. They have been and are being used to restore the bone marrow's capability of generating blood cells.

At the present time, no stem cell therapy has been used in replacing a heart valve.

Dear Dr. Donohue I would like to know the risk of having a stroke when a carotid artery has a blockage. I was told that doctors don't go by percentage of blockage now. How is the risk determined? K.C.

Answer An obstruction in the carotid artery, the neck artery that supplies the brain with blood, is not the only cause of a stroke. A piece of a blood clot that has broken off of a main clot elsewhere in the body and been swept into a brain artery is another cause of stroke. I mention this to keep it clear that a blocked carotid is but one risk for a stroke.

The doctors I know still use percentage of reduction in the interior of a carotid artery as a criterion of stroke risk. With a 60 percent to 70 percent or greater narrowing of the carotid artery, people benefit from the opening up of the artery, using a variety of procedures. Some experts feel that a 60 percent narrowing requires only blood-thinning medication, such as aspirin. Others feel that surgical removal of the blockage is indicated.

Other factors have to be considered: the patient's age, the patient's wishes and the patient's health problems unrelated to the artery problem..

Dear Dr. Donohue I am an 85-year-old female, and my doctor has suggested a colonoscopy. I find it a degrading test. The doctor didn't say why I needed it. Should a woman my age have it? K.C.

Answer The American College of Physicians recommends against screening colonoscopies for people 75 and older or for those people with a life expectancy of less than 10 years. Some add that screening can be stopped only if prior colonoscopies have been normal. No one I know recommends screening at 85.

Read the original:
A look at stem cells and their current use

Posted in Stem Cell Videos | Comments Off on A look at stem cells and their current use

A look at stem cells and their current use

Posted: September 5, 2012 at 3:20 pm

Dear Dr. Donohue Since starting to clip your articles, I haven't found any that deal with using adult stem cells for breakthrough treatments, such as repairing heart damage. Could they help if one needs an aortic valve replacement? A.R.

Answer Stem cells are primitive cells that have the potential of spawning mature cells that carry out specific bodily functions, like skin cells, liver cells, lung cells, heart muscle cells, and on and on. Embryonic stem cells have the greatest potential for differentiating into any of the many varieties of cells that make up all body organs, structures and tissues.

Hematopoietic stem cells are recovered from the bone marrow and, to a lesser extent, the circulating blood. They have been and are being used to restore the bone marrow's capability of generating blood cells.

At the present time, no stem cell therapy has been used in replacing a heart valve.

Dear Dr. Donohue I would like to know the risk of having a stroke when a carotid artery has a blockage. I was told that doctors don't go by percentage of blockage now. How is the risk determined? K.C.

Answer An obstruction in the carotid artery, the neck artery that supplies the brain with blood, is not the only cause of a stroke. A piece of a blood clot that has broken off of a main clot elsewhere in the body and been swept into a brain artery is another cause of stroke. I mention this to keep it clear that a blocked carotid is but one risk for a stroke.

The doctors I know still use percentage of reduction in the interior of a carotid artery as a criterion of stroke risk. With a 60 percent to 70 percent or greater narrowing of the carotid artery, people benefit from the opening up of the artery, using a variety of procedures. Some experts feel that a 60 percent narrowing requires only blood-thinning medication, such as aspirin. Others feel that surgical removal of the blockage is indicated.

Other factors have to be considered: the patient's age, the patient's wishes and the patient's health problems unrelated to the artery problem..

Dear Dr. Donohue I am an 85-year-old female, and my doctor has suggested a colonoscopy. I find it a degrading test. The doctor didn't say why I needed it. Should a woman my age have it? K.C.

Answer The American College of Physicians recommends against screening colonoscopies for people 75 and older or for those people with a life expectancy of less than 10 years. Some add that screening can be stopped only if prior colonoscopies have been normal. No one I know recommends screening at 85.

Visit link:
A look at stem cells and their current use

Posted in Stem Cells | Comments Off on A look at stem cells and their current use

Page 2,675«..1020..2,6742,6752,6762,677..2,6802,690..»